Skin Hyperpigmentation with Melanocortin-4 Receptor Agonists: Predictors and Prevention
Portman DJ, Simon JA, Clayton AH, et al.
The Journal of Sexual Medicine, 2020 · n = 78
Key finding
Hyperpigmentation occurred in 8% of participants; baseline melanin content was strongest predictor (OR 4.2, 95% CI 2.1-8.9).
Summary
Analysis of hyperpigmentation in bremelanotide trials, examining risk factors based on baseline skin tone and MC1R polymorphisms.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on PT-141
Comparison of PT-141 and Flibanserin for Female Sexual Desire Disorder: An Indirect Treatment Comparison
Sexual Medicine Reviews · 2022 · Review
Blood Pressure and Cardiovascular Effects of Bremelanotide in Hypertensive Versus Normotensive Women
Journal of Sexual Medicine · 2021 · Human RCT
Long-Term Safety and Efficacy of Bremelanotide: 1-Year Extension Study in Women with HSDD
The Journal of Sexual Medicine · 2021 · Human Pilot
RECONNECT-1: A Randomized Controlled Trial of Bremelanotide for Female Sexual Desire Disorder
The Journal of Sexual Medicine · 2020 · Human RCT
RECONNECT-2: Phase 3 Trial of Bremelanotide in Premenopausal Women with Generalized Hypoactive Sexual Desire Disorder
The Journal of Sexual Medicine · 2020 · Human RCT